Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Market Cap ($728.33 Million)
Market Cap & Net Worth: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (688505)
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd market cap. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (SHG:688505) has a market capitalization of $728.33 Million (CN¥4.98 Billion) as of November 8, 2026. Listed on the SHG stock exchange, this China-based company holds position #9999 globally and #2607 in its home market, demonstrating a -1.12% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's stock price CN¥7.08 by its total outstanding shares 703000000 (703.00 Million). Also see cash flow conversion of Shanghai Fudan-Zhangjiang Bio-Pharmaceut for how efficiently the company converts equity into cash flow.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Market Cap History (2020–2026)
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd market cap history from 2020 to 2026. Data shows change from $1.72 Billion to $728.33 Million (-22.43% CAGR). Check 688505 live share price for real-time trading data and today's change.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Shanghai Fudan-Zhangjiang Bio-Pharmaceut (688505) net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1.25x
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's market cap is 1.25 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $1.72 Billion | $833.80 Million | $164.66 Million | 2.07x | 10.46x |
| 2021 | $1.41 Billion | $1.14 Billion | $213.30 Million | 1.24x | 6.60x |
| 2022 | $840.14 Million | $1.03 Billion | $138.00 Million | 0.81x | 6.09x |
| 2023 | $936.27 Million | $850.73 Million | $108.63 Million | 1.10x | 8.62x |
| 2024 | $789.02 Million | $709.40 Million | $39.73 Million | 1.11x | 19.86x |
| 2025 | $853.83 Million | $685.80 Million | -$157.44 Million | 1.25x | N/A |
Competitor Companies of 688505 by Market Capitalization
Companies near Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd in the global market cap rankings as of November 8, 2026. Also see total assets of Shanghai Fudan-Zhangjiang Bio-Pharmaceut for a full breakdown of the balance sheet.
Key companies related to Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #530 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #567 globally with a market cap of $47.07 Billion USD ( CN¥321.69 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #609 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #530 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.61 |
| #567 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $47.07 Billion | CN¥50.43 |
| #609 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.80 |
Market Capitalization of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (2020–2026)
Market capitalization of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd from 2020 to today. Between 2020 and today, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's market cap moved from $1.72 Billion to $ 728.33 Million, with a yearly change of -22.43%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥728.33 Million | -14.70% |
| 2025 | CN¥853.83 Million | +8.21% |
| 2024 | CN¥789.02 Million | -15.73% |
| 2023 | CN¥936.27 Million | +11.44% |
| 2022 | CN¥840.14 Million | -40.36% |
| 2021 | CN¥1.41 Billion | -18.23% |
| 2020 | CN¥1.72 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 8th, 2026 the market cap of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $728.33 Million USD |
| MoneyControl | $728.33 Million USD |
| MarketWatch | $728.33 Million USD |
| marketcap.company | $728.33 Million USD |
| Reuters | $728.33 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., engages in the research, development, manufacture, and sale of biopharmaceutical products in the People's Republic of China. It offers photodynamic technology drugs, such as aminolevulinic acid hydrochloride and hemoporfin for Injection; doxorubicin liposome under the Libord brand; genetic engineering drugs; and oral solid preparation technol… Read more